FTC Drops AndroGel Antitrust Case Against AbbVie

By Matthew Perlman (July 30, 2021, 6:04 PM EDT) -- The Federal Trade Commission is dropping its long-running case accusing AbbVie of illegally delaying generic versions of the testosterone treatment AndroGel, saying Friday the case shows enforcers need new legislation to help them recover money for consumers.

The FTC said in a statement that it has decided to withdraw its remaining claim in the case, a claim accusing AbbVie of using an illegal reverse payment patent settlement to delay a generic version of the drug.

The commission won a $448 million penalty against AbbVie and its business partner Besins on other claims in the case, accusing the companies of using sham...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!